相关实验视频

Updated: Jul 5, 2025

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

使用机器学习预测1期淋巴瘤临床试验持续时间:深入分析和广泛应用见解

Bowen Long¹, Shao-Wen Lai², Jiawen Wu¹

¹Department of Analytics, Harrisburg University of Science and Technology, Harrisburg, PA 17101, USA.

Clinics and practice

|January 22, 2024

概括

一个新的机器学习模型准确地预测了淋巴瘤和肺癌的第一阶段临床试验持续时间. 该工具有助于临床研究规划,并可能改善瘤学患者的治疗结果.

科学领域:

在瘤学瘤学.
临床研究方法论临床研究方法论

背景情况:

淋巴瘤的诊断在美国很大,强调需要有效的临床试验流程.
第1期临床试验对于开发创新的瘤治疗方法至关重要.

研究的目的:

开发和验证一个预测模型,以评估对第一阶段临床试验预期平均持续时间的遵守.
评估模型在不同癌症类型中的有效性和多功能性.

主要方法:

来自 clinicaltrials.gov.gov 的 1089 项已完成的 1 期淋巴瘤试验的分析.
使用随机森林机器学习算法的二进制预测模型的开发.
统计验证包括准确性,ROC-AUC和置信区间.

主要成果:

随机森林模型在第一阶段淋巴瘤试验中实现了0.7248的准确性和0.7677的ROC-AUC.
与替代模型相比,该模型显示出显著的准确性.
该模型在肺癌试验中显示出多功能性,ROC-AUC为0.7701.
更高的预测概率与延长试验持续时间相关.

结论:

开发的随机森林模型有效地预测了第一阶段临床试验的持续时间.
该模型的性能和多功能性表明它有助于提高临床研究规划的效用.
改进的试验规划有可能对瘤学患者的结果产生积极影响.

关键词:

临床研究计划临床研究规划淋巴瘤临床试验临床试验机器学习预测预测试验的持续时间

更多相关视频

Predictive Immune Modeling of Solid Tumors

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

Label-Free Identification of Lymphocyte Subtypes Using Three-Dimensional Quantitative Phase Imaging and Machine Learning

Label-Free Identification of Lymphocyte Subtypes Using Three-Dimensional Quantitative Phase Imaging and Machine Learning

Published on: November 19, 2018

相关概念视频

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...